This Blueprint Neurotherapeutics Network (BPN) grant offers support for biologic-based therapeutic discovery and development, spanning from lead optimization to Phase I clinical testing. It covers various biologic products, including large macromolecules, gene-based, cell, and novel emerging therapies like microbial treatments. Awardees collaborate with NIH-funded consultants and can access NIH contract research organizations (CROs) specializing in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. A key benefit is that awardee institutions retain their intellectual property rights for biotherapeutic candidates developed through this program, gaining control over patent prosecution and licensing. This funding aims to accelerate innovative neurotherapeutics.
Opportunity ID: 356610
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-293 |
| Funding Opportunity Title: | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 01, 2024 |
| Last Updated Date: | Oct 01, 2024 |
| Original Closing Date for Applications: | Aug 18, 2027 |
| Current Closing Date for Applications: | Aug 18, 2027 |
| Archive Date: | Sep 23, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses Native American tribal governments (Federally recognized) Special district governments Private institutions of higher education Independent school districts Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-293.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 356610 Full Announcement-PAR-24-293 -> PAR-24-293-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288386 | Dec 27, 2024 | Aug 18, 2027 | View |
Package 1
Mandatory forms
356610 RR_SF424_5_0-5.0.pdf
356610 PHS398_CoverPageSupplement_5_0-5.0.pdf
356610 RR_OtherProjectInfo_1_4-1.4.pdf
356610 PerformanceSite_4_0-4.0.pdf
356610 RR_KeyPersonExpanded_4_0-4.0.pdf
356610 RR_Budget10_3_0-3.0.pdf
356610 PHS398_ResearchPlan_5_0-5.0.pdf
356610 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
356610 RR_SubawardBudget10_30_3_0-3.0.pdf
356610 PHS_AssignmentRequestForm_4_0-4.0.pdf